NCT02568397View on ClinicalTrials.gov

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Healthy
Interventions
DRUG

Lanabecestat

Administered orally

DRUG

Dabigatran etexilate

Administered orally

Trial Locations (1)

75247

Covance, Dallas

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY